«
»

Building Health, Restoring Independence

Targacept is...

Targacept, Inc. is a biopharmaceutical company advancing NNR Therapeutics™ for the treatment of various diseases and disorders. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.

Focus on:

Gastroparesis

Gastroparesis is a chronic and debilitating disorder affecting a significant number of patients with diabetes. READ MORE about our development plans for TC-6499 in this indication.

Focus on:

Our Culture

Targacept has assembled a dedicated team with years of experience in pharmaceutical development. READ MORE about our culture and aspirations.
 


 

Targacept Homepage
Targacept, NNR Therapeutics, neuronal nicotinic receptors, NNR, neuronal nicotinic acetylcholine receptors, nicotinic acetylcholine receptors, nAChR, nicotinic, nicotinic agonist, nicotinic antagonist, nervous system disorders, psychiatric disorders, nicotinic channel modulator, Parkinson’s disease, L-dopa induced dyskinesia, alpha7 modulators, alpha4beta2 modulators, AZD1446, TC-6499, gastroparesis
Targacept is a biopharmaceutical company advancing NNR Therapeutics for the treatment of various diseases and disorders.